Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
Status:
Completed
Trial end date:
2009-11-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long term safety of SCH 420814 (preladenant) in
participants with moderate to severe Parkinson's Disease who are taking an L-Dopa/dopa
decarboxylase inhibitor and/or dopamine agonist. All participants must have participated in
the main study (P04501; NCT00406029) entitled "A Phase 2, 12 Week, Double Blind, Dose
Finding, Placebo Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814
Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations
and Dyskinesias."